TELO Valuation
Telomir Pharmaceuticals Inc
$
1.560
- Overview
- Forecast
- Valuation
- Earnings
TELO Relative Valuation
TELO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TELO is overvalued; if below, it's undervalued.
Historical Valuation
Telomir Pharmaceuticals Inc (TELO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.99. The fair price of Telomir Pharmaceuticals Inc (TELO) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：1.56
Fair
-5.57
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Telomir Pharmaceuticals Inc. (TELO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Telomir Pharmaceuticals Inc. (TELO) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is -2.60. The thresholds are as follows: Strongly Undervalued below -14.91, Undervalued between -14.91 and -8.76, Fairly Valued between 3.55 and -8.76, Overvalued between 3.55 and 9.71, and Strongly Overvalued above 9.71. The current Forward EV/EBIT of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Telomir Pharmaceuticals Inc. (TELO) has a current PS of 0.00. The 5-year average PS is 5393.27. The thresholds are as follows: Strongly Undervalued below -66056.46, Undervalued between -66056.46 and -30331.60, Fairly Valued between 41118.13 and -30331.60, Overvalued between 41118.13 and 76843.00, and Strongly Overvalued above 76843.00. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Telomir Pharmaceuticals Inc. (TELO) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Telomir Pharmaceuticals Inc. (TELO) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Telomir Pharmaceuticals Inc (TELO) has a current Price-to-Book (P/B) ratio of 98.92. Compared to its 3-year average P/B ratio of 71.88 , the current P/B ratio is approximately 37.63% higher. Relative to its 5-year average P/B ratio of 71.88, the current P/B ratio is about 37.63% higher. Telomir Pharmaceuticals Inc (TELO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -4.58%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.58% , the current FCF yield is about -100.00% lower.
98.92
P/B
Median3y
71.88
Median5y
71.88
-6.12
FCF Yield
Median3y
-4.58
Median5y
-4.58
Competitors Valuation Multiple
The average P/S ratio for TELO's competitors is 0.00, providing a benchmark for relative valuation. Telomir Pharmaceuticals Inc Corp (TELO) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TELO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TELO in the past 1 year is driven by Unknown.
People Also Watch
LARK
Landmark Bancorp Inc
26.670
USD
-1.48%
CRBU
Caribou Biosciences Inc
1.930
USD
+14.20%
GGR
Gogoro Inc
0.338
USD
+4.00%
SKYX
SKYX Platforms Corp
1.320
USD
+1.54%
UEIC
Universal Electronics Inc
4.510
USD
-1.74%
STIM
Neuronetics Inc
2.840
USD
+2.16%
QUIK
Quicklogic Corp
6.270
USD
+7.92%
MMLP
Martin Midstream Partners LP
3.110
USD
+4.01%
MRAM
Everspin Technologies Inc
8.600
USD
+8.18%
AISP
Airship AI Holdings Inc
5.630
USD
-3.92%
FAQ
Is Telomir Pharmaceuticals Inc (TELO) currently overvalued or undervalued?
Telomir Pharmaceuticals Inc (TELO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.99. The fair price of Telomir Pharmaceuticals Inc (TELO) is between to according to relative valuation methord.
What is Telomir Pharmaceuticals Inc (TELO) fair value?
How does TELO's valuation metrics compare to the industry average?
What is the current P/B ratio for Telomir Pharmaceuticals Inc (TELO) as of Sep 23 2025?
What is the current FCF Yield for Telomir Pharmaceuticals Inc (TELO) as of Sep 23 2025?
What is the current Forward P/E ratio for Telomir Pharmaceuticals Inc (TELO) as of Sep 23 2025?